Wall Street analysts forecast that Baxter International Inc (NYSE:BAX) will announce $2.62 billion in sales for the current quarter, according to Zacks. Five analysts have made estimates for Baxter International’s earnings. The highest sales estimate is $2.67 billion and the lowest is $2.59 billion. Baxter International posted sales of $2.68 billion during the same quarter last year, which suggests a negative year-over-year growth rate of 2.2%. The business is scheduled to issue its next quarterly earnings report before the market opens on Thursday, April 25th.
On average, analysts expect that Baxter International will report full-year sales of $11.22 billion for the current fiscal year, with estimates ranging from $11.17 billion to $11.29 billion. For the next financial year, analysts anticipate that the company will report sales of $11.76 billion, with estimates ranging from $11.61 billion to $11.92 billion. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Baxter International.
Baxter International (NYSE:BAX) last posted its quarterly earnings results on Thursday, January 31st. The medical instruments supplier reported $0.78 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.05. Baxter International had a net margin of 14.60% and a return on equity of 19.10%. The firm had revenue of $2.84 billion for the quarter, compared to analyst estimates of $2.80 billion.
In other Baxter International news, SVP Giuseppe Accogli sold 38,297 shares of the company’s stock in a transaction on Monday, March 18th. The stock was sold at an average price of $76.78, for a total value of $2,940,443.66. Following the sale, the senior vice president now directly owns 70,001 shares in the company, valued at $5,374,676.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Jeanne K. Mason sold 37,274 shares of the company’s stock in a transaction on Thursday, January 31st. The shares were sold at an average price of $72.00, for a total value of $2,683,728.00. The disclosure for this sale can be found here. Insiders sold 82,896 shares of company stock worth $6,157,104 over the last quarter. Company insiders own 0.07% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the business. Gantzert Investment Co. LLC ADV bought a new position in Baxter International in the fourth quarter valued at approximately $25,000. Parisi Gray Wealth Management acquired a new position in Baxter International during the 4th quarter worth approximately $26,000. Sontag Advisory LLC acquired a new position in Baxter International during the 4th quarter worth approximately $30,000. Baldwin Brothers Inc. MA raised its stake in Baxter International by 904.0% during the 4th quarter. Baldwin Brothers Inc. MA now owns 502 shares of the medical instruments supplier’s stock worth $33,000 after buying an additional 452 shares during the period. Finally, We Are One Seven LLC acquired a new position in Baxter International during the 4th quarter worth approximately $34,000. 86.16% of the stock is currently owned by institutional investors.
NYSE BAX traded up $0.11 during mid-day trading on Friday, hitting $77.35. The company’s stock had a trading volume of 987,867 shares, compared to its average volume of 2,832,174. Baxter International has a 52-week low of $61.05 and a 52-week high of $78.52. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.50 and a current ratio of 2.09. The firm has a market capitalization of $39.74 billion, a price-to-earnings ratio of 25.36, a PEG ratio of 1.93 and a beta of 1.00.
The business also recently declared a quarterly dividend, which will be paid on Monday, April 1st. Shareholders of record on Friday, March 1st will be given a $0.19 dividend. This represents a $0.76 dividend on an annualized basis and a yield of 0.98%. The ex-dividend date is Thursday, February 28th. Baxter International’s dividend payout ratio (DPR) is 24.92%.
About Baxter International
Baxter International Inc provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Recommended Story: Federal Reserve
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.